Skip to content

UNRAVELLING THE ROLE OF 5-HT2AR ACTIVATION IN THE LONG-LASTING BEHAVIORAL EFFECTS OF PSILOCYBIN

Chloé Galipeau, Miguel Farinha‐ferreira, Jean-Charles Rene’ Pasquin Mariani, Samuel Diebolt, Louis Barthe, Renata Santos, Zsolt Lenkei, Ana Maria Sebastião

IBRO Neuroscience Reports October 1, 2023 DOI: 10.1016/j.ibneur.2023.08.1116 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Preclinical study Peer reviewed
Interventions Psilocybin MDL100907 Lisuride
Topics Psilocybin
Key points The text proposes to test whether 5-HT2A receptor activation is necessary and/or sufficient for psilocybin's persisting behavioral effects, using the antagonist MDL100907 and the non-psychedelic agonist lisuride. No results are reported in the abstract.

Abstract

Psilocybin is a 5-HT2AR agonist, responsible for the psychoactive effects of psychedelic mushrooms, which has recently shown therapeutic potential for several conditions, including major depressive disorder. However, the mechanisms underlying this effect, and the possibility of dissociating the psychedelic and antidepressant actions of psilocybin, remain undetermined, with preclinical research being necessary to answer these questions. Here, we aimed to assess if 5-HT2AR activation is necessary and/or sufficient for the persisting behavioral actions of psilocybin, using the 5-HT2AR antagonist MDL100907, and lisuride, a non-psychedelic 5-HT2AR and D2R agonist.

Comparable studies

Other preclinical and animal studies on psilocybin, most cited first.

Explore topics